We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Imagent (perflexane lipid microspheres)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Imagent (perflexane lipid microspheres)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Imagent (previously known as Imavist) injectable suspension has been approved by the FDA for use in patients with suboptimal echocardiograms. It is indicated for improving visualization of (opacifying) the left ventricular chamber of the heart, as well as improving the delineation of the endocardial borders (walls).

    Imagent is a synthetic product packaged as a dry powder in a ready-to-use kit. The powder is first reconstituted with water to form a suspension of microscopic spheres, or "microspheres." The solution is then injected intravenously into a patient undergoing echocardiography (ultrasound of the heart). The use of Imagent in combination with an ultrasound may better differentiate normal and abnormal heart structure and function.

    Clinical Results

    Imagent was evaluated in two randomized, controlled, multicenter trials in subjects with suboptimal echocardiograms. The two studies included a total of 409 adults with a mean age of 58.9 years. A suboptimal echocardiogram was defined as two to nine non-visualized segments (out of 12 segments) in the apical four- and two-chamber views of the baseline continuous fundamental, two-dimensional echocardiogram.

    In the trials, all Imagent-treated subjects received a single intravenous bolus injection of 0.125 mg/kg. Two-dimensional echocardiography was performed both before and after Imagent administration.

    The trials were designed to evaluate Imagent's ability to improve endocardial border delineation, ejection fraction, and wall motion scores/measurements. Independent blinded readers (three per study) scored 16 left ventricular endocardial border segments on a four-point ordinal scale for delineation and on a six-point scale for wall motion, in addition to measuring ejection fraction. The 16 segments were in three views: apical four-chamber, apical two-chamber, and apical long-axis.

    In comparing Imagent to baseline, the mean change in endocardial border delineation score was statistically significant for all readers for all three views. For ejection fraction, no improvement over non-contrast studies was observed when ejection fractions derived from echocardiography were compared to radionuclide ventriculography.

    Wall motion was analyzed in a subset of subjects with at least two adjacent segments non-evaluable in at least two of the three views on non-contrast imaging. Results showed that treatment with Imagent converted a baseline non-evaluable image to an evaluable image in 43 to 79% of the subjects, depending on the reader. In the converted images, the ability to interpret wall motion (normal vs. abnormal) improved in 10 to 46% of the subjects, also depending on the reader; however, improvement in the specific diagnostic assessments was not established.

    Side Effects

    Adverse events reported in clinical testing of Imagent include (but are not limited to) the following:

    • Headache
    • Hypertension
    • Hypotension
    • Diarrhea

    Mechanism of Action

    The active moiety, the microsphere, consists of two critical components: perflexane, the gaseous component, and DMPC, the lipid membrane component. Perflexane is chemically characterized as n-perfluorohexane, and DMPC is a semi-synthetic (not of animal origin) phospholipid. After reconstitution and intravenous injection, Imagent increases the ultrasound reflectivity of blood in the left ventricle, thereby enhancing the ultrasound signal. (from Revised Proposed Package Insert)

    Additional Information

    For additional information on Imagent, please visit www.imagentcontrast.com.

    Approval Date: 2002-06-01
    Date Created: 2002-06-12 12:00:00
    Company Name: Alliance Pharmaceutical
    Back to Listings

    Upcoming Events

    • 09Dec

      The Age of eSource: Modernizing Clinical Trials

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Patient-phsyician-consultation

      Giving Patients Back Their Voice in Clinical Trials

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing